Acadian Asset Management LLC Lowers Stock Position in Stryker Corporation $SYK

Acadian Asset Management LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 42.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 97,458 shares of the medical technology company’s stock after selling 71,190 shares during the quarter. Acadian Asset Management LLC’s holdings in Stryker were worth $38,540,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Mid American Wealth Advisory Group Inc. bought a new position in shares of Stryker during the 2nd quarter worth approximately $26,000. Sachetta LLC boosted its stake in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares in the last quarter. Ridgewood Investments LLC grew its holdings in Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in shares of Stryker during the 1st quarter valued at $37,000. Finally, Solstein Capital LLC acquired a new stake in shares of Stryker in the 2nd quarter worth $43,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on SYK shares. BTIG Research lifted their price target on Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday, September 18th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Barclays lifted their price objective on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Wells Fargo & Company upped their price objective on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Thirteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $433.37.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 520,500 shares of company stock valued at $184,803,065. 5.90% of the stock is owned by company insiders.

Stryker Stock Performance

NYSE SYK opened at $355.74 on Monday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a market cap of $136.04 billion, a PE ratio of 47.12, a P/E/G ratio of 2.66 and a beta of 0.94. The stock has a fifty day simple moving average of $374.63 and a 200-day simple moving average of $381.38. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the prior year, the firm earned $2.87 earnings per share. The firm’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.